Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 3Phase 1/2 2Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 205Breast Neoplasms 187Neoplasms 167Leukemia, Myeloid, Acute 164Multiple Myeloma 157Lymphoma 120Melanoma 117Neoplasm Metastasis 114Lymphoma, Non-Hodgkin 110Prostatic Neoplasms 109Leukemia 107Colorectal Neoplasms 96Recurrence 91Leukemia, Lymphocytic, Chronic, B-Cell 90Pancreatic Neoplasms 85Ovarian Neoplasms 85Myelodysplastic Syndromes 83Lung Neoplasms 83Lymphoma, Follicular 78Glioblastoma 78Precursor Cell Lymphoblastic Leukemia-Lymphoma 77Lymphoma, Large B-Cell, Diffuse 77Hodgkin Disease 69Lymphoma, Mantle-Cell 65Carcinoma, Renal Cell 62Brain Neoplasms 56Small Cell Lung Carcinoma 55Squamous Cell Carcinoma of Head and Neck 54Triple Negative Breast Neoplasms 52Sarcoma 52

Interventions

Sirolimus 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Epilepsy × Clear all
NCT04595513 2024-05-16

STOP2

Children's Hospital Medical Center, Cincinnati

Phase 1/2 Completed
5 enrolled 15 charts

Epilepsy, Tuberous Sclerosis

NCT01070316 2017-03-13

Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)

Children's Hospital Medical Center, Cincinnati

Phase 1/2 Completed
20 enrolled 8 charts

Epilepsy, Hereditary Sensory and Autonomic Neuropathies, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡